Free tool
FAERS Monitor: Neupogen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103353 or its brand name (Neupogen, Filgrastim). Reports on generic versions are filed under their own applications.
Reports
37,808
Serious
33,318
88% of reports
Hospitalization
17,163
Death reported
8,531
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia4,533
- neutropenia3,559
- off label use3,198
- pyrexia2,929
- diarrhoea2,297
- death2,288
- nausea2,067
- thrombocytopenia2,022
- pneumonia1,923
- fatigue1,864
- anaemia1,832
- sepsis1,511
- vomiting1,488
- white blood cell count decreased1,439
- pancytopenia1,366
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 422 |
| 2005 | 432 |
| 2006 | 483 |
| 2007 | 701 |
| 2008 | 855 |
| 2009 | 826 |
| 2010 | 895 |
| 2011 | 1,381 |
| 2012 | 1,832 |
| 2013 | 1,169 |
| 2014 | 1,372 |
| 2015 | 1,609 |
| 2016 | 1,752 |
| 2017 | 1,717 |
| 2018 | 2,275 |
| 2019 | 2,130 |
| 2020 | 2,517 |
| 2021 | 3,218 |
| 2022 | 2,982 |
| 2023 | 2,710 |
| 2024 | 2,834 |
| 2025 | 2,360 |
| 2026 | 1,333 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,016,351 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 4,533 | 40.7 | 39.6 | 164,154 |
| neutropeniaSignal | 3,559 | 14.9 | 14.5 | 45,311 |
| pancytopeniaSignal | 1,366 | 13.9 | 13.2 | 16,002 |
| thrombocytopeniaSignal | 2,022 | 10.2 | 9.8 | 16,605 |
| sepsisSignal | 1,511 | 7.6 | 7.3 | 8,620 |
| white blood cell count decreasedSignal | 1,439 | 7.5 | 7.1 | 7,993 |
| anaemiaSignal | 1,832 | 5.4 | 5.1 | 6,535 |
| pyrexiaSignal | 2,929 | 4.7 | 4.6 | 8,712 |
| pneumoniaSignal | 1,923 | 3.3 | 3.2 | 3,142 |
| off label useSignal | 3,198 | 2.0 | 2.0 | 1,750 |
| diarrhoea | 2,297 | 2.0 | 1.9 | 1,150 |
| vomiting | 1,488 | 1.8 | 1.7 | 500 |
| death | 2,288 | 1.5 | 1.4 | 368 |
| nausea | 2,067 | 1.5 | 1.4 | 303 |
| fatigue | 1,864 | 1.3 | 1.3 | 160 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.